Literature DB >> 2458336

The sequence specificity of bleomycin damage in three cloned DNA sequences that differ by a small number of base substitutions.

V Murray1, L Tan, J Matthews, R F Martin.   

Abstract

The DNA sequence specificity of the cancer chemotherapeutic agent, bleomycin, has been investigated in three clones of human alpha RI-DNA. The three 340-base pair alpha RI-DNA sequences were almost identical in their nucleotide sequence enabling the study of subtle effects of base substitutions on bleomycin cleavage. By utilizing densitometer scanning and statistical analysis of the degree of bleomycin DNA cleavage, we found 17 significant differences between the three DNA sequences. Eleven of these differences could be attributed to base substitutions close to the dinucleotide cleavage site. However, six of the differences were at positions two or more base pairs from the base substitution sites. The significant differences were up to 12 base pairs from base substitutions. It is proposed that these long range effects are due to base substitutions causing microvariation in the DNA structure to which bleomycin cleavage is sensitive.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2458336

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  The DNA sequence specificity of bleomycin cleavage in a systematically altered DNA sequence.

Authors:  Shweta D Gautam; Jon K Chen; Vincent Murray
Journal:  J Biol Inorg Chem       Date:  2017-05-16       Impact factor: 3.358

2.  Zorbamycin has a different DNA sequence selectivity compared with bleomycin and analogues.

Authors:  Jon K Chen; Dong Yang; Ben Shen; Brett A Neilan; Vincent Murray
Journal:  Bioorg Med Chem       Date:  2016-09-30       Impact factor: 3.641

3.  The degree of ultraviolet light damage to DNA containing iododeoxyuridine or bromodeoxyuridine is dependent on the DNA sequence.

Authors:  V Murray; R F Martin
Journal:  Nucleic Acids Res       Date:  1989-04-11       Impact factor: 16.971

4.  Human telomeric DNA sequences are a major target for the antitumour drug bleomycin.

Authors:  Trung V Nguyen; Vincent Murray
Journal:  J Biol Inorg Chem       Date:  2011-07-15       Impact factor: 3.358

5.  DNA structure influences sequence specific cleavage by bleomycin.

Authors:  K P Nightingale; K R Fox
Journal:  Nucleic Acids Res       Date:  1993-06-11       Impact factor: 16.971

6.  The DNA sequence specificity of bleomycin cleavage in telomeric sequences in human cells.

Authors:  Hanh T Q Nguyen; Vincent Murray
Journal:  J Biol Inorg Chem       Date:  2012-09-09       Impact factor: 3.358

7.  The genome-wide DNA sequence specificity of the anti-tumour drug bleomycin in human cells.

Authors:  Vincent Murray; Jon K Chen; Mark M Tanaka
Journal:  Mol Biol Rep       Date:  2016-05-17       Impact factor: 2.316

8.  The anti-tumor drug bleomycin preferentially cleaves at the transcription start sites of actively transcribed genes in human cells.

Authors:  Vincent Murray; Jon K Chen; Anne M Galea
Journal:  Cell Mol Life Sci       Date:  2013-08-28       Impact factor: 9.261

9.  The determination of the DNA sequence specificity of bleomycin-induced abasic sites.

Authors:  Jon K Chen; Vincent Murray
Journal:  J Biol Inorg Chem       Date:  2016-03-03       Impact factor: 3.358

Review 10.  The Interaction of the Metallo-Glycopeptide Anti-Tumour Drug Bleomycin with DNA.

Authors:  Vincent Murray; Jon K Chen; Long H Chung
Journal:  Int J Mol Sci       Date:  2018-05-04       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.